{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T08:04:17Z","timestamp":1792397057451,"version":"4.4.0"},"reference-count":58,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2020,7,1]]},"abstract":"<jats:p>Retinal gene therapy is a rapidly growing field with numerous clinical trials underway, and route of delivery is a critical contributor to its success. Subretinal administration, which involves pars plana vitrectomy in the operating room, offers targeted delivery to retinal-pigment epithelium cells and photoreceptors. Due to the immune-privileged nature of the subretinal space, the risk of an immune reaction against viral capsid antigens is minimized, an advantage of subretinal administration in patients with preexisting neutralizing antibodies. Intravitreal administration, with fewer procedure-related complications, is challenged by potential immune response and incomplete vector penetration through the internal limiting membrane. However, novel vectors, optimized by \u201cdirected evolution\u201d may address these issues. Nonsurgical in-office suprachoroidal gene delivery offers the potential for greater surface-area coverage of the posterior segment compared to focal subretinal injection, and is not hindered by the internal limiting membrane. However, the vector must pass through multiple layers to reach the targeted retinal layers, and there is a risk of immune response. This review highlights recent developments, challenges, and future opportunities associated with viral and nonviral suprachoroidal gene delivery for the treatment of chorioretinal diseases. While ocular tolerability and short-term effectiveness of suprachoroidal gene delivery have been demonstrated in preclinical models, durability of gene expression, long-term safety, potential systemic exposure, and effective delivery to the macula require further exploration. Although the safety and efficacy of suprachoroidal gene delivery are yet to be proven in clinical trials, further optimization could facilitate nonsurgical in-office suprachoroidal gene therapy.<\/jats:p>","DOI":"10.1089\/jop.2019.0126","type":"journal-article","created":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T17:43:50Z","timestamp":1586281430000},"page":"384-392","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":85,"title":["Suprachoroidal Delivery of Viral and Nonviral Gene Therapy for Retinal Diseases"],"prefix":"10.1177","volume":"36","author":[{"given":"Viral","family":"Kansara","sequence":"first","affiliation":[{"name":"Clearside Biomedical, Inc., Alpharetta, Georgia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leroy","family":"Muya","sequence":"additional","affiliation":[{"name":"Clearside Biomedical, Inc., Alpharetta, Georgia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-rei","family":"Wan","sequence":"additional","affiliation":[{"name":"Clearside Biomedical, Inc., Alpharetta, Georgia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Ciulla","sequence":"additional","affiliation":[{"name":"Clearside Biomedical, Inc., Alpharetta, Georgia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,7,24]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1080\/13816810.2018.1495745"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.181"},{"key":"e_1_3_4_4_2","unstructured":"Food & Drug Administration (internet). FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss. Available at https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-novel-gene-therapy-treat-patients-rare-form-inherited-vision-loss accessed February2 2020."},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2018.1389886"},{"key":"e_1_3_4_6_2","first-page":"69","article-title":"Gene therapy: the next frontier for treatment of acquired and inherited ocular disorders","author":"Seidman C.","year":"2015","unstructured":"Seidman C., , and Kiss S. Gene therapy: the next frontier for treatment of acquired and inherited ocular disorders. Retina Today. 69\u201371, 2015.","journal-title":"Retina Today"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2017.1356817"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2006.17.167"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2019.01.012"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2017.02.018"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2016.117"},{"key":"e_1_3_4_12_2","unstructured":"Adverum Biotechnologies. Adverum Biotechnologies reports new interim data from cohorts 1 and 2 of OPTIC Phase 1 Trial of ADVM-022 intravitreal gene therapy for wet AMD at Angiogenesis Exudation and Degeneration 2020 [Press Release] 2020. Available at http:\/\/investors.adverum.com\/news-releases\/news-release-details\/adverum-biotechnologies-reports-new-interim-data-cohorts-1-and-2 accessed February2 2020."},{"key":"e_1_3_4_13_2","unstructured":"REGENEXBIO. REGENEXBIO announces exclusive worldwide option and license agreement with Clearside Biomedical for evaluation of in-office delivery platform for RGX-314 [Press Release] 2019. Available at https:\/\/regenxbio.gcs-web.com\/news-releases\/news-release-details\/regenxbio-announces-exclusive-worldwide-option-and-license accessed February12 2020."},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2018.07.013"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2014.08.001"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.05.025"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2016.07.002"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.17-22494"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005708"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2013.64"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.01.006"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0017140"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI129085"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2018.03.008"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2017.07.013"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2015.02.021"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2018.03.001"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31868-8"},{"key":"e_1_3_4_29_2","first-page":"2","article-title":"Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability","volume":"14","author":"Sarin H.","year":"2010","unstructured":"Sarin H. Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability. Vasc. Cell. 14:2\u201314, 2010.","journal-title":"Vasc. Cell"},{"key":"e_1_3_4_30_2","unstructured":"Martorana G. Levine M. Peden M.C. et al. Comparison of suprachoroidal delivery via an Ab-Externo approach with the iTrack microcatheter versus vitrectomy and subretinal delivery for 3 different AAV serotypes for gene transfer to the retina. In: Poster presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology; May 6\u201310 2012; Fort Lauderdale FL USA. No. D748."},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1525-0016(16)33352-4"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2020.01.002"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI64833"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-7522-8_16"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2011.304"},{"key":"e_1_3_4_36_2","unstructured":"Takashima Y. Tsuchiya T. Igarashi Y. et al. Non-invasive ophthalmic liposomes for nucleic acid delivery to posterior segment of eye. europepmc.org. Available at https:\/\/europepmc.org\/abstract\/med\/23208042 (accessed August1 2019)."},{"key":"e_1_3_4_37_2","doi-asserted-by":"crossref","unstructured":"Santos A. Altamirano-Vallejo J.C. Navarro-Partida J. et al. Breaking down the barrier: topical liposomes as nanocarriers for drug delivery into the posterior segment of the eyeball. Intechopen.Com. 2019. Available at https:\/\/www.intechopen.com\/online-first\/breaking-down-the-barrier-topical-liposomes-as-nanocarriers-for-drug-delivery-into-the-posterior-seg (accessed August5 2019).","DOI":"10.5772\/intechopen.86601"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3302475"},{"key":"e_1_3_4_39_2","first-page":"1914","article-title":"Gene transfer with liposomes to the intraocular tissues by different routes of administration","volume":"37","author":"Masuda I.","year":"1996","unstructured":"Masuda I., , Matsuo T., , Yasuda T., et al. Gene transfer with liposomes to the intraocular tissues by different routes of administration. Invest. Ophthalmol. Vis. Sci. 37:1914\u20131920, 1996.","journal-title":"Invest. Ophthalmol. Vis. Sci"},{"key":"e_1_3_4_40_2","first-page":"646","article-title":"Dynamic change of collagen type I and fibronectin in posterior sclera of form-deprivation myopia after TIMP-2 gene transfect in guinea pig","volume":"29","author":"Wan L-Q","year":"2011","unstructured":"Wan L-Q, , Liu G-X, , Wang L., et al. Dynamic change of collagen type I and fibronectin in posterior sclera of form-deprivation myopia after TIMP-2 gene transfect in guinea pig. Chinese J. Exp. Ophthalmol. 29:646\u2013650, 2011.","journal-title":"Chinese J. Exp. Ophthalmol"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.visres.2007.07.012"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1021\/mp0600034"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2006.08.459"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1525-0016(16)44714-3"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0000038"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3302761"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.2217\/nnm.11.158"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddt013"},{"key":"e_1_3_4_49_2","unstructured":"Kansara V. Yoo J. Cooper M.J. et al. Suprachoroidally delivered DNA nanoparticles transfect chorioretinal cells in non-human primates and rabbits. In: Poster presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology; April 28\u2013May 2 2019; Vancouver BC. No. A0096."},{"key":"e_1_3_4_50_2","unstructured":"Taraborelli D. Noronha G. Moen R. et al. A one-week study to evaluate safety tolerability and retinal cell transfection of non-viral vectors DNA nanoparticles administered by suprachoroidal injection. In: Poster presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology; April 29\u2013May 3 2018; Honolulu Hawaii. No. C0243."},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2019.107824"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.17-23758"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2018.03.001"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1089\/hgtb.2013.212"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2018.156"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2017.00503"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.11.019"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.2174\/1389203720666190208110416"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav4523"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jop.2019.0126","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2019.0126","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2019.0126","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:43:44Z","timestamp":1777646624000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jop.2019.0126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,1]]},"references-count":58,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,7,1]]}},"alternative-id":["10.1089\/jop.2019.0126"],"URL":"https:\/\/doi.org\/10.1089\/jop.2019.0126","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,1]]}}}